Navigating 7 Analyst Ratings For Chemours

Comments
Loading...

Across the recent three months, 7 analysts have shared their insights on Chemours CC, expressing a variety of opinions spanning from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 2 1 4 0 0
Last 30D 0 0 1 0 0
1M Ago 0 0 1 0 0
2M Ago 1 1 2 0 0
3M Ago 1 0 0 0 0

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $24.57, a high estimate of $30.00, and a low estimate of $18.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 13.58%.

price target chart

Investigating Analyst Ratings: An Elaborate Study

An in-depth analysis of recent analyst actions unveils how financial experts perceive Chemours. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Michael Leithead Barclays Lowers Equal-Weight $21.00 $22.00
Duffy Fischer Goldman Sachs Lowers Neutral $23.00 $29.00
Jeffrey Zekauskas JP Morgan Lowers Neutral $18.00 $25.00
Joshua Spector UBS Lowers Buy $28.00 $30.00
John McNulty BMO Capital Lowers Outperform $30.00 $35.00
Michael Leithead Barclays Lowers Equal-Weight $22.00 $30.00
Joshua Spector UBS Raises Buy $30.00 $28.00

Key Insights:

  • Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Chemours. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Chemours compared to the broader market.
  • Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Chemours's stock. This examination reveals shifts in analysts' expectations over time.

Capture valuable insights into Chemours's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Chemours analyst ratings.

Get to Know Chemours Better

The Chemours Co is a global provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.

Unraveling the Financial Story of Chemours

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Chemours's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -6.39%. This indicates a decrease in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Chemours's net margin excels beyond industry benchmarks, reaching 4.55%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Chemours's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 9.49%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.92%, the company showcases effective utilization of assets.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 5.86.

Analyst Ratings: Simplified

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!